OBJECTIVES: The goal of this study was to investigate the effect of pre-treatment of mesenchymal stem cells (MSCs) with growth factors (GFs) on cardiomyogenic differentiation, cytoprotective action on cardiomyocytes (CMCs), and their therapeutic efficacy in myocardial infarction. BACKGROUND: Mechanisms of myocardial repair with MSC transplantation have not been fully elucidated, and therapeutic efficacy needs to be enhanced. METHODS: The MSCs obtained from the bone marrow of Fisher344 rats were treated with fibroblast growth factor-2, insulin-like growth factor-1, and bone morphogenetic protein-2. The expression of cardiac specific markers and the cytoprotective effect of MSCs with its mechanism were evaluated. Efficacy of MSCs transplantation was studied in rat myocardial infarction model. RESULTS: Treatment of MSCs with cocktails of GFs enhanced expression of cardiac transcription factors and survival. Induction of cardiac specific markers by coculture with CMCs and gap junctional communication with CMCs was more active in GF-treated MSCs than untreated MSCs. The GF-treated MSCs reduced apoptosis of neighboring CMCs in a hypoxic condition and enhanced the phosphorylated Akt and phosphorylated c-AMP response element binding protein expression of CMCs, which was markedly reduced by gap junction blockade. In a rat myocardial infarction model, transplantation of GF-treated MSCs resulted in smaller infarct size and better cardiac function than transplantation of untreated MSCs. Additionally, GF treatment enhanced gap junction formation of transplanted MSCs, which did not aggravate arrhythmia. CONCLUSIONS: Pre-treatment of MSCs with GFs enhanced cytoprotective effects on neighboring CMCs through gap junction and improved the therapeutic efficacy of MSC transplantation for myocardial repair. "Priming of MSCs with GFs" before transplantation might improve the therapeutic efficacy of cell therapy.
OBJECTIVES: The goal of this study was to investigate the effect of pre-treatment of mesenchymal stem cells (MSCs) with growth factors (GFs) on cardiomyogenic differentiation, cytoprotective action on cardiomyocytes (CMCs), and their therapeutic efficacy in myocardial infarction. BACKGROUND: Mechanisms of myocardial repair with MSC transplantation have not been fully elucidated, and therapeutic efficacy needs to be enhanced. METHODS: The MSCs obtained from the bone marrow of Fisher344 rats were treated with fibroblast growth factor-2, insulin-like growth factor-1, and bone morphogenetic protein-2. The expression of cardiac specific markers and the cytoprotective effect of MSCs with its mechanism were evaluated. Efficacy of MSCs transplantation was studied in ratmyocardial infarction model. RESULTS: Treatment of MSCs with cocktails of GFs enhanced expression of cardiac transcription factors and survival. Induction of cardiac specific markers by coculture with CMCs and gap junctional communication with CMCs was more active in GF-treated MSCs than untreated MSCs. The GF-treated MSCs reduced apoptosis of neighboring CMCs in a hypoxic condition and enhanced the phosphorylated Akt and phosphorylated c-AMP response element binding protein expression of CMCs, which was markedly reduced by gap junction blockade. In a ratmyocardial infarction model, transplantation of GF-treated MSCs resulted in smaller infarct size and better cardiac function than transplantation of untreated MSCs. Additionally, GF treatment enhanced gap junction formation of transplanted MSCs, which did not aggravate arrhythmia. CONCLUSIONS: Pre-treatment of MSCs with GFs enhanced cytoprotective effects on neighboring CMCs through gap junction and improved the therapeutic efficacy of MSC transplantation for myocardial repair. "Priming of MSCs with GFs" before transplantation might improve the therapeutic efficacy of cell therapy.
Authors: Atta Behfar; Satsuki Yamada; Ruben Crespo-Diaz; Jonathan J Nesbitt; Lois A Rowe; Carmen Perez-Terzic; Vinciane Gaussin; Christian Homsy; Jozef Bartunek; Andre Terzic Journal: J Am Coll Cardiol Date: 2010-08-24 Impact factor: 24.094
Authors: Andrew S Lee; Mohammed Inayathullah; Maarten A Lijkwan; Xin Zhao; Wenchao Sun; Sujin Park; Wan Xing Hong; Mansi B Parekh; Andrey V Malkovskiy; Edward Lau; Xulei Qin; Venkata Raveendra Pothineni; Verónica Sanchez-Freire; Wendy Y Zhang; Nigel G Kooreman; Antje D Ebert; Charles K F Chan; Patricia K Nguyen; Jayakumar Rajadas; Joseph C Wu Journal: Nat Biomed Eng Date: 2018-02-06 Impact factor: 25.671
Authors: Maira S Oliveira; Marcos B Melo; Juliana L Carvalho; Isabela M Melo; Mario Sl Lavor; Dawidson A Gomes; Alfredo M de Goes; Marilia M Melo Journal: J Cancer Sci Ther Date: 2013
Authors: Sun Wook Cho; Hyun Jin Sun; Jae-Yeon Yang; Ju Yeon Jung; Jee Hyun An; Hwa Young Cho; Hyung Jin Choi; Sang Wan Kim; Seong Yeon Kim; Dohee Kim; Chan Soo Shin Journal: Mol Ther Date: 2009-07-14 Impact factor: 11.454
Authors: Shwetha Mureli; Christopher P Gans; Dan J Bare; David L Geenen; Nalin M Kumar; Kathrin Banach Journal: Am J Physiol Heart Circ Physiol Date: 2012-12-15 Impact factor: 4.733
Authors: Jeremy L Herrmann; Troy A Markel; Aaron M Abarbanell; Brent R Weil; Meijing Wang; Yue Wang; Jiangning Tan; Daniel R Meldrum Journal: Antioxid Redox Signal Date: 2009-08 Impact factor: 8.401